Arrowhead Pharmaceuticals Corp Stock Beneish M Score

0HI3 Stock   18.58  0.05  0.27%   
This module uses fundamental data of Arrowhead Pharmaceuticals to approximate the value of its Beneish M Score. Arrowhead Pharmaceuticals M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.
  
At this time, Arrowhead Pharmaceuticals' Short and Long Term Debt Total is comparatively stable compared to the past year. Net Debt is likely to gain to about 4 M in 2024, whereas Long Term Debt is likely to drop slightly above 1.8 M in 2024.
At this time, Arrowhead Pharmaceuticals' M Score is inapplicable. The earnings manipulation may begin if Arrowhead Pharmaceuticals' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Arrowhead Pharmaceuticals executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Arrowhead Pharmaceuticals' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.56
Beneish M Score - Inapplicable
Elasticity of Receivables

0.57

Focus
Asset Quality

1.0

Focus
Expense Coverage

0.9

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

0.9

Focus
Depreciation Resistance

1.0

Focus
Net Sales Growth

1.05

Focus
Financial Leverage Condition

1.0

Focus

Arrowhead Pharmaceuticals Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Arrowhead Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables970.9 K1.6 M
Way Down
Slightly volatile
Total Revenue290.7 M276.8 M
Sufficiently Up
Slightly volatile
Total Assets924.4 M880.4 M
Sufficiently Up
Slightly volatile
Total Current Assets506.6 M482.4 M
Sufficiently Up
Slightly volatile
Non Current Assets Total417.8 M397.9 M
Sufficiently Up
Slightly volatile
Property Plant Equipment405.2 M385.9 M
Sufficiently Up
Slightly volatile
Depreciation And Amortization15.1 M14.4 M
Sufficiently Up
Slightly volatile
Selling General Administrative79.1 M83.3 M
Notably Down
Slightly volatile
Total Current Liabilities127.3 M121.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total450.3 M428.9 M
Sufficiently Up
Slightly volatile
Short Term Debt12.8 M12.1 M
Sufficiently Up
Slightly volatile
Long Term Debt1.8 M1.9 M
Notably Down
Slightly volatile
Short Term Investments353.5 M336.6 M
Sufficiently Up
Slightly volatile

Arrowhead Pharmaceuticals Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Arrowhead Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Arrowhead Pharmaceuticals in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Arrowhead Pharmaceuticals' degree of accounting gimmicks and manipulations.

About Arrowhead Pharmaceuticals Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

15.09 Million

At this time, Arrowhead Pharmaceuticals' Depreciation And Amortization is comparatively stable compared to the past year.

Arrowhead Pharmaceuticals Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Arrowhead Pharmaceuticals. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Net Receivables661.4K845.7K10.3M1.4M1.6M970.9K
Total Revenue88.0M138.3M243.2M240.7M276.8M290.7M
Total Assets522.5M710.1M691.9M765.6M880.4M924.4M
Total Current Assets322.4M384.6M376.4M419.5M482.4M506.6M
Net Debt(122.4M)(158.9M)(26.4M)4.3M3.9M4.0M
Short Term Debt1.1M4.5M5.6M10.6M12.1M12.8M
Operating Income(93.2M)(149.0M)(178.5M)(205.0M)(184.5M)(175.3M)
Investments(228.8M)(118.1M)47.4M80.6M92.7M97.3M

About Arrowhead Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.